NAGE - ChromaDex Corporation Company Cash on Hand

Chromadex Corp holds the patent rights to Nicotinamide Riboside, establishing a closed B2B ecosystem of anti-aging biotechnologies. Current cash asset levels on the GURU.Markets platform demonstrate liquidity, with the current mark equal to 0.07. Stable cash flow is supported by regular dietary supplement sales, while a productive R&D cycle in cellular metabolism ensures the systematic release of innovative biomedical components.
Financial and market metric breakdowns for ChromaDex (NAGE)

This indicator tracks the remaining liquid assets, determining the gap between operating cash flow and actual business maintenance costs. By analyzing the volume of physical cash, an investor assesses the financial autonomy of Chromadex Corp (NAGE), which is critical for securing long-term biomedical R&D projects and the development of innovative nutraceuticals without the need for emergency external debt financing.